Condition Directory

Parkinson's Disease clinical trials

Directory of U.S. ClinicalTrials.gov public records for Parkinson's Disease. Browse Parkinson's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 2, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

208

Shown on this page

Current sort

How Parkinson's Disease studies are organized in the registry

Records generally use the registry spelling “Parkinson disease.” The portfolio mixes drug studies with a high share of device, exercise, and rehabilitation research, so the study-type filter is unusually useful here. Disease-stage language (“early,” “advanced,” “levodopa-treated”) commonly appears in titles.

Terms that often appear in related listings

early Parkinson deep brain stimulation levodopa gait

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 208 matching trials for Parkinson's Disease.

Live ClinicalTrials.gov results.

Active filters: "early Parkinson" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions: NEU-411, Placebo; Drug · Other
Lead sponsor: Neuron23 Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more

Conditions: Parkinson Disease
Interventions: BHV-8000 10mg, BHV-8000 20 mg, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Irvine, California • Los Angeles, California + 21 more

Conditions: Parkinson, Parkinson Disease
Interventions: Neuroimaging, Quantitative assessments; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Parkinson Disease 6, Early-Onset, Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human, Parkinson Disease Autosomal Recessive, Early Onset, Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PD - Parkinson's Disease
Interventions: Medtronic Percept Deep Brain Stimulation (adaptive DBS), Medtronic Percept Deep Brain Stimulation (cDBS); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 25 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson's Disease
Interventions: RO7046015, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more

Conditions: Parkinsons Disease
Interventions: Prasinezumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more

Conditions: Parkinson's Disease
Interventions: Standard of Care; Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more

Conditions: Parkinson's Disease
Interventions: Prasinezumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more

Conditions: Parkinson Disease, GBA Gene Mutation, Gaucher Disease
Interventions: PET scan, neuroQWERTY; Diagnostic Test
Lead sponsor: Pacific Parkinson's Research Centre; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Georgetown, Texas

Conditions: Parkinson's Disease, Essential Tremor, Dystonia
Interventions: Medtronic Activa Tremor Control System, Deep Brain Stimulation; Device · Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

About this Parkinson's Disease clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Parkinson's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Parkinson's Disease.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Parkinson's Disease clinical trials

How Parkinson's Disease studies are organized in the registry

Filter and sort this condition

Live official records

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Neuroplasticity in Parkinson's Disease

Hereditary Parkinson s Disease Natural History Protocol

Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

The GBA Multimodal Study in Parkinson's Disease

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Deep Brain Stimulation Surgery for Movement Disorders

About this Parkinson's Disease clinical trials directory page